John's mailing address filed with the SEC is 4105 E. MADISON STREET, SUITE 320, SEATTLE, WA, 98112.
Over the last 12 years, insiders at Atossa Therapeutics Inc have traded over 114,740$ worth of Atossa Therapeutics Inc stock and bought 274,300 units worth 204,285$ . The most active insiders traders include Gregory L Weaver、Steven C Quay、Shu Chih Chen. On average, Atossa Therapeutics Inc executives and independent directors trade stock every 205 days with the average trade being worth of 38,260$. The most recent stock trade was executed by Jonathan Finn on 10 April 2024, trading 25,000 units of ATOS stock currently worth 44,250$.
atossa therapeutics, inc. develops and markets medical devices, laboratory tests, and therapeutics to address breast health conditions in the united states. the company's lead program is the development of endoxifen, an active metabolite of tamoxifen which is in phase ii studies to treat and prevent breast cancer. it is also developing intraductal microcatheter technology to target the delivery of therapies, including fulvestrant, immunotherapies, and chimeric antigen receptor t-cell therapies, directly to the site of breast cancer. the company was formerly known as atossa genetics inc. and changed its name to atossa therapeutics, inc. in january 2020. atossa therapeutics, inc. was founded in 2009 and is headquartered in seattle, washington.
Atossa Therapeutics Inc executives and other stock owners filed with the SEC include: